News
Determining outcomes pertaining to healthy ageing trials
At the recent UK SPINE conference there were a series of workshops facilitating a diverse range of discussions. One of these was on the topic of the outcome measures suitable for…
New report published by Mel Calvert
UK SPINE researcher Mel Calvert publishes report: Patient reported outcome assessment must be inclusive and equitable. Read it here.
An Interview with MultiplAI
Sixty million people die each year. Eighteen million die of cardiovascular problems. It is the biggest global killer.
The World Deaths Per year, How Many Deaths in The World Per year…
Machine learning contributes to advances in surrogate end points for cardiovascular clinical trials
One of the great challenges in improving health in old age is measuring how well someone is ageing. An individual who is “aging well” will be less likely to get ill than someone of…
Ageing research hits the headlines
UK SPINE welcomes the recent Babraham Institute announcement that they have successfully rejuvenated skin cells in the lab. This discovery, and the associated press coverage, is an…
A new national focus on health ageing
UK SPINE welcomes the recent announcement of 11 new networks, across 28 UK universities, aimed at transforming UK ageing research. The £2m investment by UKRI recognises the need to…
UK SPINE creating connections for multi-disciplinary drug discovery and development in healthy ageing via our Translational Fund projects
At the end of last year UK SPINE awarded a series of Translational Fund projects to support research at the earliest stages of translation. By facilitating discussion amongst this…
UK SPINE receives additional funding and starts the next phase of work
The UK SPINE, with its central aim to accelerate drug discovery for healthy ageing, has been awarded £1.64m from Research England’s Connecting Capability Fund (CCF) for a new…
A roadmap for the discovery of therapeutics in healthy ageing
This document produced in collaboration with colleagues at the Medicines Discovery Catapult, a UK SPINE partner, is a guide to established best practice in drug discovery with a focus…
Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab
The phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s disease and also slowed the accumulation of tau…